Patwardhan, V. et al. Differences across the lifespan between females and males in the top 20 causes of disease burden globally: a systematic analysis of the Global Burden of Disease Study 2021. Lancet Public Health 9, e282–e294 (2024).
Regitz-Zagrosek, V. & Gebhard, C. Gender medicine: effects of sex and gender on cardiovascular disease manifestation and outcomes. Nat. Rev. Cardiol. 20, 236–247 (2023).
Scott, P. E. et al. Participation of women in clinical trials supporting FDA approval of cardiovascular drugs. J. Am. Coll. Cardiol. 71, 1960–1969 (2018).
Spiering, A. E. et al. Underrepresentation of women in cardiovascular disease clinical trials—what’s in a name? Int J. Cardiol. Heart Vasc. 55, 101547 (2024).
van der Bijl, M. F. et al. Sex differences in permanent discontinuation of trial medication in chronic coronary artery disease: the LoDoCo2 trial. J. Am. Heart Assoc. 14, e040412 (2025).
Saw, J. et al. Canadian spontaneous coronary artery dissection cohort study: in-hospital and 30-day outcomes. Eur. Heart J. 40, 1188–1197 (2019).
Singh, T. et al. Takotsubo syndrome: pathophysiology, emerging concepts, and clinical implications. Circulation 145, 1002–1019 (2022).
Vrints, C. et al. 2024 ESC Guidelines for the management of chronic coronary syndromes. Eur. Heart J. 45, 3415–3537 (2024).
McDonagh, T. A. et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur. Heart J. 42, 3599–3726 (2021).
Byrne, R. A. et al. 2023 ESC Guidelines for the management of acute coronary syndromes. Eur. Heart J. 44, 3720–3826 (2023).
McDonagh, T. A. et al. 2023 focused update of the 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur. Heart J. 44, 3627–3639 (2023).
Vogel, B. et al. The Lancet Women and Cardiovascular Disease Commission: reducing the global burden by 2030. Lancet 397, 2385–2438 (2021).
El Khoudary, S. R. et al. Menopause transition and cardiovascular disease risk: implications for timing of early prevention: a scientific statement from the American Heart Association. Circulation 142, e506–e532 (2020).
van Oosterhout, R. E. M. et al. Sex differences in symptom presentation in acute coronary syndromes: a systematic review and meta-analysis. J. Am. Heart Assoc. 9, e014733 (2020).
Farb, A. et al. Coronary plaque erosion without rupture into a lipid core. A frequent cause of coronary thrombosis in sudden coronary death. Circulation 93, 1354–1363 (1996).
Cao, M. et al. Systematic review of sex-specific high sensitivity cardiac troponin I and T thresholds. Clin. Ther. 46, 988–994 (2024).
Lee, K. K. et al. Sex-specific thresholds of high-sensitivity troponin in patients with suspected acute coronary syndrome. J. Am. Coll. Cardiol. 74, 2032–2043 (2019).
Kimenai, D. M. et al. Sex-specific versus overall clinical decision limits for cardiac troponin I and T for the diagnosis of acute myocardial infarction: a systematic review. Clin. Chem. 64, 1034–1043 (2018).
Liu, L. et al. Sex-specific absolute delta thresholds for high-sensitivity cardiac troponin T. Clin. Chem. 68, 441–449 (2022).
Rivera, F. B. et al. Participation of women in cardiovascular trials from 2017 to 2023: a systematic review. JAMA Netw. Open 8, e2529104 (2025).
Cho, L. et al. Increasing participation of women in cardiovascular trials: JACC Council perspectives. J. Am. Coll. Cardiol. 78, 737–751 (2021).
Nidorf, S. M. et al. Colchicine in patients with chronic coronary disease. N. Engl. J. Med 383, 1838–1847 (2020).
Khan, L., Khan, M. & Rzayev, N. Reassessing colchicine efficacy in women: the need for sex-stratified cardiovascular evidence. Eur. J. Prev. Cardiol. 33, 801 (2025).
Parikh, N. I. et al. Adverse pregnancy outcomes and cardiovascular disease risk: unique opportunities for cardiovascular disease prevention in women: a scientific statement from the American Heart Association. Circulation 143, e902–e916 (2021).
de Simone, G., Devereux, R. B., Daniels, S. R. & Meyer, R. A. Gender differences in left ventricular growth. Hypertension 26, 979–983 (1995).
Beale, A. L., Meyer, P., Marwick, T. H., Lam, C. S. P. & Kaye, D. M. Sex differences in cardiovascular pathophysiology: why women are overrepresented in heart failure with preserved ejection fraction. Circulation 138, 198–205 (2018).
St Pierre, S. R., Peirlinck, M. & Kuhl, E. Sex matters: a comprehensive comparison of female and male hearts. Front. Physiol. 13, 831179 (2022).
Litviňuková, M. et al. Cells of the adult human heart. Nature 588, 466–472 (2020).
Schulz, A. et al. Sex-specific impairment of cardiac functional reserve in HFpEF: insights from the HFpEF Stress Trial. JACC Adv. 2, 100327 (2023).
Rijnbeek, P. R. et al. Normal values of the electrocardiogram for ages 16-90 years. J. Electrocardiol. 47, 914–921 (2014).
Vicente, J., Johannesen, L., Galeotti, L. & Strauss, D. G. Mechanisms of sex and age differences in ventricular repolarization in humans. Am. Heart J. 168, 749–756 (2014).
Pham, T. V. & Rosen, M. R. Sex, hormones, and repolarization. Cardiovasc. Res. 53, 740–751 (2002).
Li, M. & Ramos, L. G. Drug-induced QT prolongation and torsades de pointes. P T 42, 473–477 (2017).
Weizman, O. et al. Incidence of cardiac arrest during sports among women in the European Union. J. Am. Coll. Cardiol. 81, 1021–1031 (2023).
Li, L., Le Douairon Lahaye, S., Ding, S. & Schnell, F. Sex differences in the incidence of sudden cardiac arrest/death in competitive athletes: a systematic review and meta-analysis. Sports Med. 55, 697–712 (2025).
Hiteshi, A. K. et al. Gender differences in coronary artery diameter are not related to body habitus or left ventricular mass. Clin. Cardiol. 37, 605–609 (2014).
Stegehuis, V. E. et al. Impact of clinical and haemodynamic factors on coronary flow reserve and invasive coronary flow capacity in non-obstructed coronary arteries: a patient-level pooled analysis of the DEBATE and ILIAS studies. EuroIntervention 16, e1503–e1510 (2021).
Mikail, N. et al. Imaging of heart disease in women: review and case presentation. Eur. J. Nucl. Med. Mol. Imaging 50, 130–159 (2022).
Patel, M. B., Bui, L. P., Kirkeeide, R. L. & Gould, K. L. Imaging microvascular dysfunction and mechanisms for female-male differences in CAD. JACC Cardiovasc. Imaging 9, 465–482 (2016).
Katritsis, D. et al. Wall shear stress: theoretical considerations and methods of measurement. Prog. Cardiovasc. Dis. 49, 307–329 (2007).
Cunningham, K. S. & Gotlieb, A. I. The role of shear stress in the pathogenesis of atherosclerosis. Lab. Invest. 85, 9–23 (2005).
Meteva, D. et al. Acute coronary syndrome with plaque erosion: clinical characteristics, mechanisms, and unmet needs. Eur. Heart J. 47, 1403–1414 (2025).
Adlam, D. et al. Spontaneous coronary artery dissection: pitfalls of angiographic diagnosis and an approach to ambiguous cases. JACC Cardiovasc. Interv. 14, 1743–1756 (2021).
Tweet, M. S. et al. Clinical features, management, and prognosis of spontaneous coronary artery dissection. Circulation 126, 579–588 (2012).
McMurray, J. J. V. et al. Effects of sacubitril-valsartan versus valsartan in women compared with men with heart failure and preserved ejection fraction: insights from PARAGON-HF. Circulation 141, 338–351 (2020).
Nunez Gil, I. J. et al. Characterization of Tako-tsubo cardiomyopathy in Spain: results from the RETAKO National Registry. Rev. Esp. Cardiol. 68, 505–512 (2015).
Ghadri, J. R. & Templin, C. The InterTAK registry for takotsubo syndrome. Eur. Heart J. 37, 2806–2808 (2016).
Crooijmans, C. et al. Safety, feasibility, and diagnostic yield of invasive coronary function testing: Netherlands Registry of Invasive Coronary Vasomotor Function Testing. JAMA Cardiol. 10, 384–390 (2025).
Reis, S. E. et al. Coronary flow velocity response to adenosine characterizes coronary microvascular function in women with chest pain and no obstructive coronary disease. Results from the pilot phase of the Women’s Ischemia Syndrome Evaluation (WISE) study. J. Am. Coll. Cardiol. 33, 1469–1475 (1999).
Reynolds, H. R. et al. Coronary arterial function and disease in women with no obstructive coronary arteries. Circ. Res. 130, 529–551 (2022).
Miner, S. et al. Endotypes of angina with non-obstructive coronary arteries: a prospective multicentre study. Eur. Heart J. 47, 594–604 (2026).
Bucciarelli-Ducci, C., Luscher, T. & Crea, F. A new definition of MINOCA: from infarction to injury. Eur. Heart J.47, 4255–4258 (2026).
Pasupathy, S., Air, T., Dreyer, R. P., Tavella, R. & Beltrame, J. F. Systematic review of patients presenting with suspected myocardial infarction and nonobstructive coronary arteries. Circulation 131, 861–870 (2015).
Lawless, M. et al. Sex differences in treatment and outcomes amongst myocardial infarction patients presenting with and without obstructive coronary arteries: a prospective multicentre study. Eur. Heart J. Open 3, oead033 (2023).
Zucker, I. & Prendergast, B. J. Sex differences in pharmacokinetics predict adverse drug reactions in women. Biol. Sex. Differ. 11, 32 (2020).
Peters, S. A. E. et al. Sex differences in high-intensity statin use following myocardial infarction in the United States. J. Am. Coll. Cardiol. 71, 1729–1737 (2018).
Watson, S., Caster, O., Rochon, P. A. & den Ruijter, H. Reported adverse drug reactions in women and men: aggregated evidence from globally collected individual case reports during half a century. EClinicalMedicine 17, 100188 (2019).
Bots, S. H. et al. Sex differences in reported adverse drug reactions to angiotensin-converting enzyme inhibitors. JAMA Netw. Open 5, e228224 (2022).
Bots, S. H. & den Ruijter, H. M. Recommended heart failure medications and adverse drug reactions in women. Circulation 139, 1469–1471 (2019).
Bots, S. H. et al. Heart failure medication dosage and survival in women and men seen at outpatient clinics. Heart 107, 1748–1755 (2021).
Santema, B. T. et al. Identifying optimal doses of heart failure medications in men compared with women: a prospective, observational, cohort study. Lancet 394, 1254–1263 (2019).
Rathore, S. S., Wang, Y. & Krumholz, H. M. Sex-based differences in the effect of digoxin for the treatment of heart failure. N. Engl. J. Med 347, 1403–1411 (2002).
Rossello, X. et al. Beta-blockers after myocardial infarction: effects according to sex in the REBOOT trial. Eur. Heart J. 47, 701–715 (2026).
Occhipinti, G. et al. Sex differences in dual antiplatelet therapy de-escalation strategies after percutaneous coronary intervention: a network meta-analysis. Eur. Heart J. 47, 1901–1913 (2026).
Kempers, E. K. et al. Sex differences in outcomes of vitamin K antagonist treatment in patients with a mechanical heart valve: a Dutch population-based cohort study. J. Thromb. Haemost. 24, 955–970 (2025).
Spiering, A. E. et al. Sex chromosomes and cardiovascular disease. Eur. J. Prev. Cardiol. 33, 316–326 (2026).
Sambola, A. et al. Sex-based differences in percutaneous coronary intervention outcomes in patients with ischaemic heart disease. Eur. Cardiol. 18, e06 (2023).
Schmidt, A. F. et al. Unravelling the difference between men and women in post-CABG survival. Front. Cardiovasc. Med. 9, 768972 (2022).
Harik, L. et al. Sex differences in coronary artery bypass graft surgery outcomes: a narrative review. J. Thorac. Dis. 15, 5041–5054 (2023).
Torregrossa, G. et al. Sex-specific differences in coronary blood flow dynamics during coronary artery bypass surgery. J. Cardiothorac. Surg. 21, 405 (2026).
van Pelt, L. et al. Resynchronising care: addressing sex differences in cardiac resynchronisation therapy. EClinicalMedicine 94, 103894 (2026).
Arshad, A. et al. Cardiac resynchronization therapy is more effective in women than in men: the MADIT-CRT (Multicenter Automatic Defibrillator Implantation Trial with Cardiac Resynchronization Therapy) trial. J. Am. Coll. Cardiol. 57, 813–820 (2011).
Zusterzeel, R. et al. Cardiac resynchronization therapy in women: US Food and Drug Administration meta-analysis of patient-level data. JAMA Intern. Med. 174, 1340–1348 (2014).
Cheng, A. et al. Potential mechanisms underlying the effect of gender on response to cardiac resynchronization therapy: insights from the SMART-AV multicenter trial. Heart Rhythm 9, 736–741 (2012).
Anne Dual, S. et al. Does size matter for female continuous-flow LVAD recipients? A translational approach to a decade long question. ASAIO J. 68, 21–27 (2022).
Nakamura, M. et al. Gender difference and outcomes in HeartMate 3 left ventricular assist device support: results from the J-MACS registry. J. Cardiol. 86, 525–532 (2025).
Prendergast, T. W. et al. The role of gender in heart transplantation. Ann. Thorac. Surg. 65, 88–94 (1998).
Khush, K. K., Kubo, J. T. & Desai, M. Influence of donor and recipient sex mismatch on heart transplant outcomes: analysis of the International Society for Heart and Lung Transplantation Registry. J. Heart Lung Transpl. 31, 459–466 (2012).
Reue, K. & Wiese, C. B. Illuminating the mechanisms underlying sex differences in cardiovascular disease. Circ. Res. 130, 1747–1762 (2022).
Berthois, Y., Katzenellenbogen, J. A. & Katzenellenbogen, B. S. Phenol red in tissue culture media is a weak estrogen: implications concerning the study of estrogen-responsive cells in culture. Proc. Natl Acad. Sci. USA 83, 2496–2500 (1986).
Waldhorn, I. et al. Modeling sex differences in humans using isogenic induced pluripotent stem cells. Stem Cell Rep. 17, 2732–2744 (2022).
Paulis, M. et al. Chromosomal instability in mouse-induced pluripotent stem cells: insights into X and Y aneuploidies. Cytogenet. Genome Res. 166, 67–78 (2025).
Naik, H. C. et al. Lineage-specific dynamics of loss of X upregulation during inactive-X reactivation. Stem Cell Rep. 19, 1564–1582 (2024).
Tukiainen, T. et al. Landscape of X chromosome inactivation across human tissues. Nature 550, 244–248 (2017).
Consortium GT The GTEx Consortium atlas of genetic regulatory effects across human tissues. Science 369, 1318–1330 (2020).
Oliva, M. et al. The impact of sex on gene expression across human tissues. Science 369, eaba3066 (2020).
Hartman, R. J. G. et al. Intrinsic transcriptomic sex differences in human endothelial cells at birth and in adults are associated with coronary artery disease targets. Sci. Rep. 10, 12367 (2020).
Shi, W. et al. Cardiac proteomics reveals sex chromosome-dependent differences between males and females that arise prior to gonad formation. Dev. Cell 56, 3019–34 (2021).
Diez Benavente, E. et al. Female gene networks are expressed in myofibroblast-like smooth muscle cells in vulnerable atherosclerotic plaques. Arterioscler. Thromb. Vasc. Biol. 43, 1836–1850 (2023).
Sakkers, T. R. et al. Atherosclerotic fibrous plaques in women present ECM remodeling linked to TGF-β. Circ. Res. 138, e327624 (2026).
Hartman, R. J. G. et al. Sex-stratified gene regulatory networks reveal female key driver genes of atherosclerosis involved in smooth muscle cell phenotype switching. Circulation 143, 713–726 (2021).
Wits, M., Becher, C., de Man, F., Sanchez-Duffhues, G. & Goumans, M. J. Sex-biased TGFβ signalling in pulmonary arterial hypertension. Cardiovasc. Res. 119, 2262–2277 (2023).
Adlam, D. et al. Genome-wide association meta-analysis of spontaneous coronary artery dissection identifies risk variants and genes related to artery integrity and tissue-mediated coagulation. Nat. Genet. 55, 964–972 (2023).
Morselli, E. et al. The effects of oestrogens and their receptors on cardiometabolic health. Nat. Rev. Endocrinol. 13, 352–364 (2017).
Tabassum, R., Widen, E. & Ripatti, S. Effect of biological sex on human circulating lipidome: an overview of the literature. Atherosclerosis 384, 117274 (2023).
Roeters van Lennep, J. E. et al. Women, lipids, and atherosclerotic cardiovascular disease: a call to action from the European Atherosclerosis Society. Eur. Heart J. 44, 4157–4173 (2023).
Suthahar, N., Meems, L. M. G., Ho, J. E. & de Boer, R. A. Sex-related differences in contemporary biomarkers for heart failure: a review. Eur. J. Heart Fail 22, 775–788 (2020).
Holven, K. B. & Roeters van Lennep, J. Sex differences in lipids: a life course approach. Atherosclerosis 384, 117270 (2023).
Woloshin, S. & Schwartz, L. M. Distribution of C-reactive protein values in the United States. N. Engl. J. Med 352, 1611–1613 (2005).
Blumenthal, R. S. et al. ACC/AHA/AACVPR/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Dyslipidemia: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines.J. Am. Coll. Cardiol. 87, 2624–2757 (2026).
Koprulu, M. et al. Sex differences in the genetic regulation of the human plasma proteome. Nat. Commun. 16, 4001 (2025).
van de Hoef, T. P. The coronary sinus reducer as a game-changer for the treatment of coronary microvascular dysfunction. JACC Cardiovasc. Inter. 17, 2905–2907 (2024).
Giannini, F. et al. Use of a novel, self-expanding coronary sinus reducer to treat symptomatic epicardial and microvascular ischemic heart disease: preclinical and first-in-human experience. J. Soc. Cardiovasc. Angiogr. Inter. 5, 104070 (2026).
Sagris, M. et al. Drug-coated balloons and bioresorbable scaffolds in spontaneous coronary artery dissections. J. Clin. Med. 14, 8751 (2025).
Brown, H. et al. A systematic review of healthcare experiences of women and men living with coronary heart disease. npj Womens Health 2, 40 (2024).
Mc Causland, F. R. et al. Angiotensin receptor neprilysin inhibition and cardiovascular outcomes across the kidney function spectrum: the PARAGON-HF Trial. JACC Heart Fail. 13, 105–114 (2025).
Solomon, S. D. et al. Dapagliflozin in heart failure with mildly reduced or preserved ejection fraction. N. Engl. J. Med 387, 1089–1098 (2022).
Peters, S. A. E. et al. Sample size considerations to assess sex-related treatment effects. Eur. Heart J. 47, 1790–1798 (2026).
Matthews, A. A. et al. Benchmarking observational analyses before using them to address questions trials do not answer: an application to coronary thrombus aspiration. Am. J. Epidemiol. 191, 1652–1665 (2022).
Matthews, A. A. et al. Prospective benchmarking of an observational analysis in the SWEDEHEART registry against the REDUCE-AMI randomized trial. Eur. J. Epidemiol. 39, 349–361 (2024).
Dimitriadis, K. et al. ANOCA updated: from pathophysiology to modern clinical practice. Cardiovasc. Revasc. Med. 71, 1–10 (2024).
Samuels, B. A. et al. Comprehensive management of ANOCA, part 1-definition, patient population, and diagnosis: JACC state-of-the-art review. J. Am. Coll. Cardiol. 82, 1245–1263 (2023).
Manfrini, O. et al. Sex and gender differences in coronary pathophysiology and ischaemic heart disease. Eur. Heart J. 47, 2727–2749 (2026).
Jansen, T. P. J. et al. Sex differences in coronary function test results in patient with angina and nonobstructive disease. Front. Cardiovasc. Med. 8, 750071 (2021).
Keshvani, N. et al. Sex differences in long-term outcomes following acute heart failure hospitalization: findings from the Get With The Guidelines-Heart Failure registry. Eur. J. Heart Fail. 25, 1544–1554 (2023).
Deng, Y. et al. Sex differences in mortality and hospitalization in heart failure with preserved and mid-range ejection fraction: a systematic review and meta-analysis of cohort studies. Front. Cardiovasc. Med. 10, 1257335 (2023).
Alabas, O. A. et al. Sex differences in treatments, relative survival, and excess mortality following acute myocardial infarction: national cohort study using the SWEDEHEART registry. J. Am. Heart Assoc. 6, e007123 (2017).
Wang, S. et al. Sex disparity in characteristics, management, and in-hospital outcomes of patients with ST-segment elevated myocardial infarction: insights from Henan STEMI Registry. Cardiol. Res. Pract. 2022, 2835485 (2022).
Qamar, A. et al. Clinical profiles, outcomes, and sex differences of patients with STEMI: findings from the NORIN-STEMI Registry. JACC Asia 3, 431–442 (2023).
Lee, C. Y. et al. Sex and gender differences in presentation, treatment and outcomes in acute coronary syndrome, a 10 year study from a multi-ethnic Asian population: the Malaysian National Cardiovascular Disease Database-Acute Coronary Syndrome (NCVD-ACS) registry. PLoS One 16, e0246474 (2021).
Weight, N. et al. Sex-based analysis of NSTEMI processes of care and outcomes by hospital: a nationwide cohort study. Eur. Heart J. Qual. Care Clin. Outcomes 10, 750–762 (2024).
Ang, S. P. et al. Sex differences and clinical outcomes in patients with myocardial infarction with nonobstructive coronary arteries: a meta-analysis. J. Am. Heart Assoc. 13, e035329 (2024).
Hochman, J. S. et al. Baseline characteristics and risk profiles of participants in the ISCHEMIA randomized clinical trial. JAMA Cardiol. 4, 273–286 (2019).
Steg, P. G. et al. Heart rate and use of beta-blockers in stable outpatients with coronary artery disease. PLoS One 7, e36284 (2012).
Ford, T. J. et al. Stratified medical therapy using invasive coronary function testing in angina: the CorMicA Trial. J. Am. Coll. Cardiol. 72, 2841–2855 (2018).
Gitto, M., Gentile, F., Nowbar, A. N., Chieffo, A. & Al-Lamee, R. Gender-related differences in clinical presentation and angiographic findings in patients with ischemia and no obstructive coronary artery disease (INOCA): a single-center observational registry. Int. J. Angiol. 29, 250–255 (2020).
Templin, C. et al. Clinical features and outcomes of Takotsubo (stress) cardiomyopathy. N. Engl. J. Med 373, 929–938 (2015).
Murakami, T. et al. Gender differences in patients with takotsubo cardiomyopathy: multi-center registry from Tokyo CCU Network. PLoS One 10, e0136655 (2015).
Chen, S. et al. Spontaneous coronary artery dissection: clinical characteristics, management, and outcomes in a racially and ethnically diverse community-based cohort. Perm J. 23, 18.278 (2019).
Correction to: 2024 ESC Guidelines for the management of chronic coronary syndromes: developed by the task force for the management of chronic coronary syndromes of the European Society of Cardiology (ESC) Endorsed by the European Association for Cardio-Thoracic Surgery (EACTS). Eur. Heart J.46, 1565 (2025).
